BANGKOK - Docquity, Southeast Asia’s largest community of healthcare professionals (HCPs), and global biopharmaceutical leader AstraZeneca developed ...

FDA advisors said that more data are needed to fully understand if there are broader safety concerns related to use of respiratory syncytial virus ... possible vaccine-associated enhanced ...

"So, adjuvant-enhanced ... 1345 RSV vaccine mRESVIA was not covered in the present report. The study was supported by grants from the National Institute of Allergy and Infectious Diseases and ...

More than 35,000 cases of the mosquito-borne disease have been reported on the French Indian Ocean island since August 2024.

The highest risk of transmission of SARS-CoV-2 was in the first 72 hours at room temperature and first 24 hours at 37℃.

Global analytics software leader, FICO, will announce its second quarter fiscal 2025 results on April 29, 2025, after the market closes and will host a conference call on April 29th at 5:00 p.m.

Munich news, health insurance, technology, jobs and other topics for expatriates. The Eye Newspapers covers daily news and offers services for foreigners.

59 years of age who are at increased risk of severe RSV disease receive a single dose of RSV vaccine ... Lumenis Unveils Enhanced SPLENDOR Xtm Laser Hair Removal Solution with New Clinical ...

Decoy Therapeutics, Inc. (Decoy), a privately held preclinical biopharmaceutical company engineering the next generation of peptide conjugate therapeutics, announces that Massachusetts Institute of ...

Table 01: Global Respiratory Syncytial Virus Vaccine Market Value (US$ Mn) Forecast, By Vaccine Type, 2020-2035 Table 02: Global Respiratory Syncytial Virus Vaccine Market Value (US$ Mn) Forecast, By ...